ReviewProgress in neuro-psychopharmacology & biological psychiatry2026
Ang II-mediated effects on BBB integrity in psychiatric and neurological disorders.
Review in Progress in neuro-psychopharmacology & biological psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurovascular unit remodeling: focusing on glial cells in stroke injury and recovery.Frontiers in cellular neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alterations of the blood-brain barrier (BBB) integrity and permeability is a critical factor implicated in several brain pathologies, including stress-related and neurodegenerative disorders. Growing evidence suggests that the renin-angiotensin system (RAS), a key regulator of vascular homeostasis, also plays a significant role in the pathogenesis and progression of these neurological conditions. Notably, angiotensin II (Ang II) and its downstream signaling pathways contribute to the modulation of BBB properties, directly impacting brain health. While the pharmacological targeting of the RAS has been extensively explored and shown to alleviate neurological and psychiatric symptoms, the molecular mechanisms underlying the complex crosstalk between Ang II and the BBB in these disorders remain insufficiently understood. In this review, we highlight the current literature supporting the contribution of Ang II and its type 1 and type 2 receptor-mediated signaling pathways to the structural and functional integrities of the BBB. We systematically gathered and analyzed relevant studies describing how Ang II disrupts BBB function across various pathological contexts, with an emphasis on stress-related disorders, neurodegenerative diseases and traumatic brain injury (TBI). This consolidated understanding helps refine future research questions and guide hypothesis-driven studies to better dissect the mechanisms underlying the relationship between Ang II signaling and BBB vulnerability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.